BioAtla Q4 net loss narrows on lower expenses

Bioatla

31/03/2026 21:31

Overview

US biotechnology firm's Q4 net loss narrowed year-over-year on lower operating expenses

Company generated $2 mln in Q4 collaboration revenue, up from zero a year earlier

BioAtla began formal process to monetize assets and implemented restructuring to cut costs

Result Drivers

COST REDUCTIONS - Lower R&D and G&A expenses due to workforce reductions, program prioritization, and reduced stock-based compensation

COLLABORATION REVENUE - $2 mln milestone payment from Context Therapeutics under license agreement contributed to Q4 revenue

STRATEGIC REVIEW - Company initiated a formal process to monetize assets and is re-evaluating clinical program timing to preserve capital

Company press release: ID:nGNXc6X4lG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$9.78 mln
Q4 Operating Expenses
$11.26 mln
Q4 Operating Income
-$9.26 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)